Hematology Activities
Novel Reversal Agents to Safely and Effectively Treat Direct Oral Anticoagulant Bleeding: Education for the Health-System Pharmacist
0290-0000-21-132-L01-P
Analyze clinical data and real-world evidence comparing the safety benefits of specific reversal agents over prothrombin complex concentrates for reversing life-threatening DOAC-related bleeding
6-01-2021
1.00
Managed Care Strategies to Support Access to CAR T-Cell Therapy
0290-0000-21-081-L01-P
This live webinar will examine recent studies for approved and emerging chimeric antigen receptor-modified T cell (CAR T-cell) therapies and the impact of these treatments on the future paradigm of cancer care.
5-11-2021
1.00
New and Emerging Management Strategies for Acute Graft-Versus-Host Disease in Hematopoietic Stem Cell Transplant
0290-0000-21-026-H01-P
This activity will review clinical data for new and emerging strategies in aGVHD prevention and treatment, the role of biomarkers, and the role of the pharmacist in patient care.
1.50
Decreasing Mortality Rates When Reversing DOAC-Related Bleeding: Examining Updated Recommendations, New Data, and Real-World Evidence Using Specific Reversal Agents
0290-0000-20-402-H01-P
This article guideline recommendations for DOAC reversal, real-world evidence, and strategies to ensure appropriate use of DOAC reversal agents.
2.00